CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Biohaven Q3 2026 net loss narrows 25% to $129.28 million

By Public Technologies
  • Biohaven’s third-quarter 2026 net loss narrowed 25% year over year to $129.28 million.
  • Research and development expenses fell 28% to $101.85 million, primarily due to lower direct program and preclinical spending.
  • The SK Biopharmaceuticals licensing agreement provides $400 million in cash consideration, including $350 million payable at closing.
  • The FDA paused new opakalim enrollment pending additional nonclinical safety studies; RISE 3 topline results remain expected in second-half 2026.
  • The FDA accepted the Vyglxia application resubmission for spinocerebellar ataxia, assigning a first-quarter 2027 user fee goal date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610291602PR_NEWS_USPR_____NE84836) on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk